PORTFOLIO NEWS Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek® October 15, 2023 Read More » Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update October 12, 2023 Read More » Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Spontaneous Urticaria October 12, 2023 Read More » Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium October 10, 2023 Read More » Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting October 9, 2023 Read More » Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy October 5, 2023 Read More » Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy October 5, 2023 Read More » Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration October 2, 2023 Read More » Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes September 27, 2023 Read More » Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Inducible Urticaria September 25, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek® October 15, 2023 Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update October 12, 2023 Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Spontaneous Urticaria October 12, 2023 Read More »
Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium October 10, 2023 Read More »
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting October 9, 2023 Read More »
Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy October 5, 2023 Read More »
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy October 5, 2023 Read More »
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration October 2, 2023 Read More »
Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes September 27, 2023 Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Inducible Urticaria September 25, 2023 Read More »